Medical Board releases new guidelines for practitioners and students on blood-borne viruses

Medical Board of Australia, 23 Jun 2020

The Medical Board of Australia is encouraging practitioners and students to review the new Guidelines for registered health practitioners and students in relation to blood-borne viruses before they take effect on 6 July 2020.

The Board’s guidelines are for practitioners and students who perform exposure-prone procedures and registered health practitioners who are treating registered health practitioners or students living with a blood-borne virus who perform exposure-prone procedures.

 

 

 

COVID-19 and viral hepatitis FAQs  in English, Korean, Chinese

Hepatitis NSW, May 2020

Since the COVID-19 virus is so new and can be life threatening, there are many unknown factors at play. This is even more so for people with pre-existing health conditions to consider. To help address those concerns and to answer the frequently asked questions, Hepatitis NSW has now compiled a number of online resources. 

All pages are based on the most up to date information and will be updated frequently.

 

Factsheet: Your rights and responsibilities when living with hepatitis B or hepatitis C

Hepatitis Australia,  23 April 2020

This brief factsheet provides an overview of peoples’ rights and responsibilities when living with hepatitis B or hepatitis C.

New COVID Taskforce website from ASHM

ASHM, UPDATED ON: 14 April 2020

ASHM’s Taskforce on BBVs, Sexual Health and COVID-19 was established on 20 March 2020. It provides a timely opportunity for the BBV and sexual health sectors to discuss the scientific, clinical, BBV and sexual health service delivery and social implications of COVID-19, and provides consistent and evidence-based messaging to the health workforce, sector partners and community.

The website contains interim recommendations on:

  • adults living with HIV
  • adults living with chronic hepatitis B.
  • adults living with hepatitis C, or the complications of previous hepatitis C infection
  • people who are incarcerated in criminal justice settings during the COVID-19 pandemic including those who are living with HIV, hepatitis B and hepatitis C.

 

Nurse Practitioner (s100) Prescribing Change

Hepatitis Australia, 3 April 2020

Hepatitis Australia warmly welcomes recent changes to the Pharmaceutical Benefits Scheme (PBS) allowing authorised Nurse Practitioners to prescribe hepatitis B and hepatitis C medicines under the Highly Specialised Drugs (s100) Program.

Both hepatitis B and hepatitis C are under-treated and without improvement in a range of areas Australia risks falling short of agreed national and global viral hepatitis elimination goals. Expanded access to timely treatment and care is a critical component of the national response.

This important development acknowledges the clinical expertise of Nurse Practitioners and the therapeutic relationships they develop and maintain with highly stigmatised and often vulnerable populations.

Under previous arrangements, authorised Nurse Practitioners were able to prescribe treatments for hepatitis B and hepatitis C under the PBS General Schedule (s85). Where Nurse Practitioners were available in primary care services, this arrangement enhanced access to antiviral therapies in community settings.

From 1 April 2020, authorised Nurse Practitioners are also able to prescribe hepatitis B and hepatitis C treatments under the Highly Specialised Drugs (s100) Program. This matters because some people are not able to access primary care settings. The change therefore improves the availability of treatment for vulnerable populations such as people living in remote and regional areas, people experiencing homelessness, and people in custodial settings.

Hepatitis Australia congratulates the Pharmaceutical Benefits Advisory Committee for recommending this important change, and we thank our colleagues at ASHM (Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine) for their leadership in this matter.

Community members in need of more information about hepatitis B and hepatitis C may wish to contact 1800 437 222 (1800 HEP ABC). This National Hepatitis Infoline directs callers to the community-based hepatitis organisation in the relevant state or territory.

ASHM’s “Find a Prescriber” function helps community members find a Doctor or Nurse Practitioner who has attended ASHM’s hepatitis training. People can also speak to their GP about treatment.

https://ashm.org.au/news/pbac-endorse-np-prescribing-for-hepatitis-b-hepatitis-c-and-hiv-medicines/

and

http://www.pbs.gov.au/info/news/2020/04/authorised-nurse-practitioners-now-eligible-to-prescribe

—————————————————————————————————————

The above information was found here 

Coronavirus disease (COVID-19), HIV & hepatitis C: What you need to know

CATIE (Canada), 17 March 2020

  • An HIV-positive person on effective treatment is not expected to be at higher risk of becoming seriously ill with COVID-19
  • A person with untreated HIV or a low CD4+ cell count may be at higher risk of becoming seriously ill with COVID-19
  • People with HIV or hepatitis C are more likely to have other conditions that carry a greater risk of becoming seriously ill with COVID-19